Imikeraderm (Imiquimod)

Imiquimod is a Toll‑like receptor 7 (TLR7) agonist. When applied to the skin it binds TLR7 on immune cells, triggering a cascade that releases cytokines such as interferon‑α and interleukin‑12. These mediators stimulate antiviral and antitumor activity directly at the site of application.

The dosage regimen for Imikeraderm is determined by the prescribing clinician based on the specific indication, lesion size and patient factors. The product is supplied as a topical preparation and should be applied exactly as directed on the prescription label.

Safety data for imiquimod in pregnancy and lactation are limited. The product should only be used if the prescriber judges that the potential benefit outweighs any possible risk to the fetus or infant. Women who are pregnant or nursing should discuss alternatives with their healthcare provider.

To request Imikeraderm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

For external genital warts, imiquimod (Imikeraderm) offers a topical immune‑modulating approach, whereas alternatives such as podophyllotoxin or cryotherapy act by direct cytotoxicity. Imiquimod may require longer treatment periods but can be applied by the patient at home, reducing the need for procedural visits.

Imikeraderm should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from excess moisture and direct light. Do not freeze. Keep the container tightly closed when not in use to maintain stability.

Imikeraderm is a topical preparation applied directly to the affected skin area. The prescriber will specify the amount (e.g., a thin layer) and frequency (e.g., once daily, three times per week). Hands should be washed before and after application, and the treated area should be covered only if instructed.

Serious adverse events, though uncommon, include severe skin reactions such as ulceration or necrosis, allergic contact dermatitis, and systemic flu‑like symptoms (fever, chills, fatigue). Patients should seek medical attention promptly if they experience extensive ulceration, widespread rash, or systemic illness.

Imikeraderm is contraindicated in individuals with known hypersensitivity to imiquimod or any excipients in the formulation. It should be avoided on broken, infected or inflamed skin, and used with caution in immunocompromised patients. Pregnant or breastfeeding women should only use it if the prescriber determines that benefits outweigh potential risks.